Enanta Pharmaceuticals has linked its respiratory syncytial virus (RSV) antiviral to significant reductions in viral load and ...
Enanta Pharmaceuticals' EDP-323 shows promising Phase 2a trial results, significantly reducing RSV viral load and symptoms ...
Leerink Partners analyst Roanna Ruiz maintained a Hold rating on Enanta Pharmaceuticals (ENTA – Research Report) yesterday. The ...
Enanta Pharmaceuticals announced positive topline results from a Phase IIa trial of EDP-323, its RSV replication inhibitor, ...
Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With RSV ...
In a report released today, Roy Buchanan from JMP Securities reiterated a Buy rating on Enanta Pharmaceuticals (ENTA – Research Report), ...
Discover Enanta Pharmaceuticals' groundbreaking patent for HBV-inhibiting compounds, offering new hope for effective hepatitis B treatments and improved patient outcomes.
Watertown, Massachusetts Saturday, September 28, 2024, 18:00 Hrs [IST] ...
New data show Talvey’s potential in multiple myeloma drug combinations. Elsewhere, AbbVie got more positive Parkinson’s drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback